Annandale, VA; August 17, 2020
The Clinical Alliance for Research and Education (CARE-ID) Reaches 50% Enrollment for the Blaze-1 COVID-19 Clinical Trial
CARE-ID is very pleased to report it has reached 50% of its target for participants receiving their treatment infusions. “We were not entirely sure how strong a response we’d get when we began. Starting up this study was very fast compared to other studies we’ve done in the past,” said Steve Poretz, RN, MSHA, Executive Director at CARE-ID. “Happily, the response has been very good so far for this very important clinical research study.” Sponsored by Eli Lilly and Company (Lilly), the BLAZE-1 Study is evaluating a potential COVID-19 antibody treatment following successful results in the laboratory setting. As of August 14th, hundreds of participants have enrolled in the study nation-wide and have received the one-time, one-hour infusion in the outpatient setting. To continue making its progress, CARE-ID is looking for additional adults in the Northern Virginia area ages 18 or older to participate in the study who have recently tested positive for COVID-19 and are not hospitalized.